Join the club for FREE to access the whole archive and other member benefits.

Michael Kope

Co-Chief Executive Officer and Co-founder Underdog Pharmaceuticals

Established SENS Research Foundation in 2009 with Aubrey de Grey, and was its founding CEO, serving until 2019.

Received his J.D. from the University of Michigan in 1990. He has served as the University of Michigan’s Intellectual Property Counsel; Director of Corporate Development for Aviron/MedImmune, Inc.; and as CEO and officer of a number of biotechnology startups.

Visit website:


See also: Company Cyclarity Therapeutics - Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases.

Mentioned in this Resource

SENS Research Foundation

Non-profit organization focused on transforming the way the world researches and treats age-related diseases

Michael Kope is also referenced in the following:

SENS Annual Report 2020

Quick summary of SENS’ latest research projects and other activities

Michael Kope News

Reason reports back from October's Rejuvenation Startup Summit

Fight Aging! - 19-Oct-2022

Some really exciting developments with quite a few in clinical trials


Racing for the lead... Underdog becomes Cyclarity Therapeutics

Longevity Technology - 20-Jun-2022

Also announces move to Buck Institute for Research on Aging


Underdog pharmaceuticals secures $10m funding from Kizoo ventures

Longevity Technology - 23-Sep-2021

Funds to bring affordable and effective age-related therapies to the public